Can the blind see? Participant guess about treatment arm assignment may influence outcome in a clinical trial of bupropion for smoking cessation

Journal of Substance Abuse Treatment

Volumn 34, Issue 2, 2008, Pages 234-241

  Schnoll, Robert A ^a   Epstein, Leonard ^b   Audrain, Janet ^a   Niaura, Raymond ^c   Hawk, Larry ^b   Shields, Peter G ^d   Lerman, Caryn ^a   Wileyto, E Paul ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c BUTLER HOSPITAL   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

Author keywords

Blind bias; Bupropion; Mediators; Smoking cessation; Study blind

Indexed keywords

AMFEBUTAMONE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD CHANGE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ADULT; BIAS (EPIDEMIOLOGY); BUPROPION; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 38849171196     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2007.04.004     Document Type: Article

References (37)

1. Ahluwalia J.S., Harris K.J., Catley D., Okuyemi K.S., and Mayo M.S. Sustained release bupropion for smoking cessation in African Americans: A randomized controlled trial. Journal of the American Medical Association 288 (2002) 468-474
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV. 4th ed. (1994) Washington, DC
3. Bang H., Ni L., and Davis C.E. Assessment of blinding in clinical trials. Controlled Clinical Trials 25 (2004) 143-156
4. Baron R.M., and Kenny D.A. The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. Journal of Personality and Social Psychology 51 (1986) 1173-1182
5. Carpenter J.A. Contributions from psychology to the study of drinking and driving. Quarterly Journal of Studies on Alcohol Suppl 4 (1968) 234-251
6. Collins B., Wileyto P., Patterson F., Rukstalis M., Audrain-McGovern A., Kaufmann V., et al. Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine and Tobacco Research 6 (2004) 27-37
7. Desbiens N.A. In randomized controlled trials, should subjects in both placebo and drug groups be expected to guess that they are taking drug 50% of the time?. Medical Hypotheses 59 (2002) 227-232
8. Epstein L.H., Wright S.M., Paluch R.A., Leddy J.J., Hawk L.W., Jaroni J.L., et al. Relation between food reinforcement and dopamine genotypes and its effect on food intake in smokers. American Journal of Clinical Nutrition 80 (2004) 82-88
9. Fagerström K.O., Kunze M., Schoberberger R., Breslau N., Hughes J.R., Hurt R.D., et al. Nicotine dependence versus smoking prevalence: Comparisons among countries and categories of smokers. Tobacco Control 5 (1996) 52-56
10. Fiore M.C., Bailey W.C., Cohen S.J., Dorfman S.F., Goldstein M.G., Gritz E.R., et al. Treating tobacco use and dependence. Clinical practice guideline (2000), USDHHS, Rockville, MD
11. Goodwin J.C. Research in psychology: Methods and design (1995), John Wiley and Sons, New York
12. Guess H.A., Kleinman A., Kusek J.W., and Engel L.W. The science of the placebo (2002), BMJ Books, London
13. Hall S.M., Humfleet G.L., Reus V.I., Munoz R.F., Hartz D.T., and Maude-Griffin R. Psychological intervention and antidepressant treatment in smoking cessation. Archives of General Psychiatry 59 (2002) 930-936
14. Heatherton T.F., Kozlowski L.T., Frecker R.C., and Fagerström K.O. The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction 86 (1991) 1119-1127
15. Henningfield J.E., Fant R.V., Buchhalter A., and Stitzer M.L. Pharmacotherapy for nicotine dependence. CA: A Cancer Journal for Clinicians 55 (2005) 281-299 (quiz 322-283, 325)
16. Hughes J., Hatsukami D., Pickens R.W., Krahn D., Malin S., and Luknic A. Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology (Berl) 83 (1984) 82-87
17. Hughes J., Stead L., and Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews CD000031 (2004)
18. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine 340 (1999) 685-691
19. Killen J.D., Fortmann S.P., Murphy G.M., Hayward C., Arredondo C., and Cromp D. Extended treatment with bupropion SR for cigarette smoking cessation. Journal of Consulting and Clinical Psychology 74 (2006) 286-294
20. Killen J.D., Robinson T.N., Ammerman S., Hayward C., Rogers J., Stone C., et al. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. Journal of Consulting and Clinical Psychology 72 (2004) 729-735
21. Lerman C., Berrettini W., Pinto A., Patterson F., Crystal-Mansour S., Wileyto E.P., et al. Changes in food reward following smoking cessation: A pharmacogenetic investigation. Psychopharmacology (Berl) 174 (2004) 571-577
22. Lerman C., Jepson C., Wileyto E.P., Epstein L.H., Rukstalis M., Patterson F., et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: Results of two randomized clinical trials. Neuropsychopharmacology 31 (2006) 231-242
23. Lerman C., Niaura R., Collins B.N., Wileyto P., Audrain-McGovern J., Pinto A., et al. Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychology of Addictive Behaviors 18 (2004) 362-366
24. Lerman C., Roth D., Kaufmann V., Audrain J., Hawk L., Liu A., et al. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug and Alcohol Dependence 67 (2002) 219-223
25. Lerman C., Shields P.G., Wileyto E.P., Audrain J., Hawk L.H., Pinto A., et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychology 22 (2003) 541-548
26. Lerman C., Shields P.G., Wileyto E.P., Audrain J., Pinto A., Hawk L., et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 12 (2002) 627-634
27. Mooney M., White T., and Hatsukami D. The blind spot in the nicotine replacement therapy literature: Assessment of the double-blind in clinical trials. Addictive Behaviors 29 (2004) 673-684
28. Perkins K., Grobe J., D'Amicao D., Fonte C., Wilson A., and Stiller R. Low dose nicotine nasal spray use and effects during initial smoking cessation. Experimental and Clinical Psychopharmacology 4 (1996) 157-165
29. Perkins K., Sayette M., Conklin C., and Caggiula A. Placebo effects of tobacco smoking and other nicotine intake. Nicotine and Tobacco Research 5 (2003) 695-709
30. Piasecki T., Niaura R., Shadel W., Abrams D., Goldstein M., Fiore M., et al. Smoking withdrawal dynamics in unaided quitters. Journal of Abnormal Psychology 109 (2000) 74-86
31. Simon J.A., Duncan C., Carmody T.P., and Hudes E.S. Bupropion for smoking cessation: A randomized trial. Archives of Internal Medicine 164 (2004) 1797-1803
32. Society for Research on Nicotine and Tobacco. Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and smoking cessation. Nicotine and Tobacco Research 4 (2002) 149-159
33. Wagena E.J., Knipschild P.G., Huibers M.J., Wouters E.F., and van Schayck C.P. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine 165 (2005) 2286-2292
34. Ward M.M., Swan G.E., and Jack L.M. Self-reported abstinence effects in the first month after smoking cessation. Addictive Behaviors 26 (2001) 311-327
35. Watson D., Clark L., and Tellegen A. Development and validation of brief measures of positive and negative affect: The PANAS scales. Journal of Personality and Social Psychology 54 (1988) 1063-1070
36. Wileyto E.P., Patterson F., Niaura R., Epstein L., Brown R., Audrain-McGovern J., et al. Do small lapses predict relapse to smoking behavior under bupropion treatment. Nicotine and Tobacco Research 6 (2004) 357-366
37. Wileyto E.P., Patterson F., Niaura R., Epstein L.H., Brown R.A., Audrain-McGovern J., et al. Recurrent event, analysis of lapse and recovery in a smoking cessation clinical trial utilizing bupropion. Nicotine and Tobacco Research 7 (2005) 257-268